GW Pharmaceuticals Reports Fiscal First Quarter 2018 Financial Results and Operational Progress

Pharmaceutical Investing

GW Pharmaceuticals (NASDAQ:GWPH) a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial results for the first quarter ended 31 December 2017. As quoted in the press release: “With the Epidiolex regulatory applications accepted for review in both the US and Europe, and an assigned mid-year …

As quoted in the press release:

“With the Epidiolex regulatory applications accepted for review in both the US and Europe, and an assigned mid-year FDA decision date, 2018 is expected to be an exciting year for our Company with an anticipated first U.S. approval and launch. The commercial teams are making great progress toward launching Epidiolex with full conviction,” stated Justin Gover, GW’s Chief Executive Officer.

Click here to read the full press release.

cannabinoid europe fda financial results gw pharmaceuticals nasdaq:gwph therapeutics us Company News